PCSK9-targeted treatments, which include monoclonal antibody therapies and siRNA therapeutics, are highly efficacious in lowering LDL cholesterol on top of statin therapy. Availble in English, Spanish and Japanese, this booklet/slidedeck, the second in the series, overview the clinical trials with these novel therapies in different high-risk patient groups. These include the landmark outcomes studies - FOURIER and ODYSSEY OUTCOMES - which definitively demonstrated reduction in residual cardiovascular risk among patients with stable cardiovascular disease or acute coronary syndrome. Subscribe to the R3i website and download this free booklet now ➡️ https://lnkd.in/e_m_JpBq #R3i #ResidualRisk #ResidualRiskReduction #MedicalResearch #ResidualCardiovascularRisk #Cholesterol
R3i Foundation (Residual Risk Reduction)
E-Learning
A call to action to reduce residual vascular risk in dyslipidemic patients
Info
The Residual Risk Reduction initiative (R3i) is a worldwide, academic, multidisciplinary, non-profit, Swiss-law foundation established by international academic and clinical experts in recognition of the significant residual risk of macro-vascular events and micro-vascular complications, including risk from established risk factors (such as unhealthy lifestyles, dyslipidemia, high blood pressure, high blood sugar and obesity) as well as emerging risk factors, that persists in patients despite treatment with current, evidence-based medical care. The R3i Foundation was formed to engage healthcare professionals in an innovative, global initiative focused on supporting academic research, professional and patient education and public health advocacy with the goal of significantly improving and extending the lives of millions of patients at risk for vascular events. For more information about the R3i Foundation, please visit www.r3i.org
- Website
-
http://www.r3i.org
Externer Link zu R3i Foundation (Residual Risk Reduction)
- Branche
- E-Learning
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- 4052 Basel
- Art
- Nonprofit
- Gegründet
- 2007
Orte
-
Primär
St. Alban-Anlage 46
4052 Basel, CH
Beschäftigte von R3i Foundation (Residual Risk Reduction)
Updates
-
The management of residual cardiovascular risk continues to evolve with innovative approaches in sight. Recent studies have highlighted the potential of RNA interference (RNAi) therapies, such as ARO-ANG3, which targets angiopoietin-like protein 3 (ANGPTL3). The therapy has shown promising results in reducing triglycerides by up to 70% in clinical trials, paving the way for better management of lipid-related residual risk. As we advance, these novel strategies could transform the landscape of cardiovascular treatment. Read the complete editorial on our website. ➡️ https://lnkd.in/ePJUwEBQ #CardiovascularHealth #InnovativeTherapies #LipidManagement #RNAi #ClinicalTrials
-
Lowering low-density lipoprotein cholesterol (LDL-C) with bempedoic acid reduced major adverse cardiovascular events in high-risk patients unable to tolerate statin therapy. Learn more here ➡️ https://lnkd.in/ePyEFu7G #BempedoicAcid #CardioTwitter
-
Residual risk remains a challenge. How can we reduce it? Despite reaching treatment goals, many patients still face high residual risk of cardiovascular events. Learn more about the latest strategies and therapies being researched to tackle this issue, on our website ➡️ www.r3i.org #R3i #ResidualRisk #ResidualRiskReduction #MedicalResearch #CVD #Cardiovascular #CardiovascularEvents #CardiovascularDisease
-
The prevalence of diabetes among patients with atherosclerotic cardiovascular disease (ASCVD) has nearly doubled, according to NHANES. This alarming trend underscores the need for enhanced strategies to manage diabetes alongside other cardiovascular risk factors. Let's work towards better control and prevention. Find out more about Diabetes and ASCVD on our website ➡️ https://lnkd.in/ecfrKXSP #R3i #ResidualRisk #ResidualRiskReduction #Cardiovascular #CardiovascularHealth #CardiovascularRisk #CardiovascularDisease #CVD #NHANES #Diabetes #DiabetesAwareness #ASCVD
-
Cholesterol efflux is the first step in reverse cholesterol transport (RCT), the removal of cholesterol from macrophage foam cells in the arterial wall by HDL, transport in plasma, uptake by the liver and ultimate secretion into the bile. Visit the #R3i library to find all the latest content related to cholesterol and cardiovascular research. ➡️ https://www.r3i.org #Cholesterol #CholesterolEfflux #ReverseCholesterolTransport #RCT #HDL
-
Impaired cholesterol efflux is linked to higher cardiovascular event rates, especially in patients with stable coronary artery disease and recent myocardial infarction (MI). The AEGIS-II trial explored whether CSL-112, an innovative intravenous formulation of apoA-I, could enhance cholesterol efflux and reduce recurrent major adverse cardiovascular events. However, the trial's results showed no significant reduction in the primary endpoint, leaving questions about the role of cholesterol efflux in cardiovascular risk management. Find out more on our website ➡️ https://lnkd.in/eG-AWRJ9 #R3i #ResidualRisk #ResidualRiskReduction #MedicalResearch #ClinicalTrials #Cardiovascular #CardiovascularEvents #CardiovascularHealth #CardiovascularRisk #CardiovascularDisease #CVD #Cholesterol #CholesterolEfflux
-
The latest NHANES data reveals that progress in managing key cardiovascular risk factors like blood pressure and non-HDL cholesterol has stalled. Despite initial gains, the past decade has seen little improvement. It's time to refocus on effective interventions to combat these stagnating trends and improve heart health. Read the complete publication on our website ➡️ https://lnkd.in/ecfrKXSP #R3i #ResidualRisk #ResidualRiskReduction #Cardiovascular #CardiovascularHealth #CardiovascularRisk #CardiovascularDisease #CVD #HeartHealth #RiskFactors #NHANES #Cholesterol
-
To substantially extend and improve the lives of patients with heart disease and/or diabetes who have atherogenic dyslipidemia and remain at significantly increased risk of vascular diseases including heart attacks, impaired kidney function, loss of sight and limb amputation despite receiving current standards of care. Learn more here ➡️ https://lnkd.in/ehDumCY #R3i #ResidualRisk #ResidualRiskReduction #ResidualRiskReductionInitiative #MedicalResearch
-
The AEGIS-II trial aimed to reduce the rate of recurrent major cardiovascular events in high-risk acute MI patients using CSL-112, an apoA-I infusion. Despite the promising rationale, the trial did not show significant reductions in cardiovascular deaths, MIs, or strokes at 90, 180, or 365 days. These findings challenge the potential of CSL-112 to address residual cardiovascular risk. Learn more about the results of this study on our website ➡️ https://lnkd.in/eG-AWRJ9 #R3i #ResidualRisk #ResidualRiskReduction #MedicalResearch #ClinicalTrials #Cardiovascular #CardiovascularEvents #CardiovascularHealth #CardiovascularRisk #CardiovascularDisease #CVD